Table 4.

Incremental value of LS in predicting cardiovascular outcomes (primary composite outcomes, CV death, incident HF hospitalization, and total number of HF hospitalizations) beyond clinical and echocardiographic variables (n=319). Clinical variables were: age, gender, race, randomization strata (prior HF hospitalization or biomarker criteria), region of enrollment (Americas versus Russia or Georgia), randomized treatment assignment, core lab LVEF, history of atrial fibrillation, heart rate, New York Heart Association class, history of stroke, creatinine, and hematocrit. Echocardiographic variables of LV structure were LV mass and LVESVi. Only individuals with no missing data for any clinical or echocardiographic variables were included.

	Base cross- validated C statistic	+LS cross- validated C statistic	P value	IDI (95% CI)	P value	NRI (95% CI)	P value
Primary (events =86)
Clinical	0.69 (0.63–0.75)	0.72 (0.66–0.77)	0.069	4.2 (0.2–9.8)	0.024	29.8 (0.0–40.4)	0.048
Clinical + structure	0.70 (0.64–0.76)	0.72 (0.67–0.78)	0.059	3.9 (0.3–9.0)	0.028	25.2 (2.6–39.8)	0.032
Clinical + structure + E/E’	0.71 (0.65–0.77)	0.73 (0.67–0.78)	0.098	2.7 (0.0–7.7)	0.048	18.3 (-0.1–37.1)	0.056
CV death (events = 43)
Clinical	0.64 (0.56–0.71)	0.71 (0.63–0.79)	0.038	8.8 (1.2–18.5)	0.008	42.5 (8.2–55.7)	0.016
Clinical + structure	0.67 (0.59–0.74)	0.73 (0.65–0.80)	0.064	8.6 (1.1–17.3)	0.012	38.6 (8.5–52.8)	0.004
Clinical + structure + E/E’	0.66 (0.58–0.74)	0.72 (0.65–0.80)	0.068	7.9 (1.2–17.2)	0.024	37.2 (7.9–54.1)	0.012
HF Hosp (events = 57)
Clinical	0.71 (0.64–0.78)	0.72 (0.65–0.80)	0.42	2.0 (–0.4–8.2)	0.12	15.1 (−17.5–33.4)	0.26
Clinical + structure	0.72 (0.65–0.79)	0.73 (0.66–0.80)	0.35	2.1 (–0.3–7.5)	0.14	15.0 (−12.4–34.8)	0.20
Clinical + structure + E/E’	0.74 (0.67–0.80)	0.74 (0.67–0.81)	0.79	0.9 (−0.4–5.4)	0.19	10.5 (−14.9–29.2)	0.32